Bio-pharma: A financialized business model

Critical Perspectives on Accounting

Volumn 21, Issue 7, 2010, Pages 631-641

  Andersson, Tord ^a   Gleadle, Pauline ^b   Haslam, Colin ^a   Tsitsianis, Nick ^a  

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^b OPEN UNIVERSITY   (United Kingdom)

Author keywords

Bio pharma; Business model; Financialization; Shareholder value

Indexed keywords

EID: 77956485572     PISSN: 10452354     EISSN: 10959955     Source Type: Journal    
DOI: 10.1016/j.cpa.2010.06.006     Document Type: Article

References (26)

1. Andersson T., Haslam C., Lee E., Tsitsianis N. Financialized accounts: a stakeholder account of cash distribution in the S&P 500 (1990-2005). Accounting Forum 2007, 31(3):217-232.
2. Barney J.B. Firm resources and sustained competitive advantage. Journal of Management 1991, (17):99-120.
3. Bridgers A. Finding the prime target: acquisition ideas for the new pharma business model 2009, Nerac Consulting. http://www.nerac.com/nerac_insights.php?category=articles&id=218.
4. Carpenter M., Lazonick W., O'Sullivan M. The stock market and innovative capability in the new economy: the optical networking industry. Industrial and Corporate Change 2003, 12(5):963-1034.
5. Department for Culture Media and Sport (DCMS) Creative industries mapping document 1998, Creative Task Force. http://webarchive.nationalarchives.gov.uk/+/http://www.culture.gov.uk/reference_library/publications/4740.aspx/.
6. Department for Culture Media and Sport (DCMS) Creative industries mapping document 2001, Creative Task Force. http://webarchive.nationalarchives.gov.uk/+/http://www.culture.gov.uk/reference_library/publications/4632.aspx.
7. Ernst & Young. Beyond borders: global biotechnology report; 2009. http://www.ey.com/Publication/vwLUAssets/Beyond_borders_2009/$FILE/Beyond_borders_2009.pdf.
8. Ernst & Young. Beyond borders: global biotechnology report; 2008. http://www.ey.com/Publication/vwLUAssets/Industry_Biotechnology_Beyond_Borders_2008/$FILE/Biotechnology_Beyond_Borders_2008.pdf.
9. Froud J., Johal S., Leaver A., Williams K. Financialisation, strategy and governance: or what management has become. Critical management studies conference 2003, http://www.mngt.waikato.ac.nz/ejrot/cmsconference/2003/abstracts/criticalaccounting/Froud.pdf.
10. Froud J., Johal S., Leaver A., Williams K. Financialization and strategy: narrative and numbers 2006, Routledge, Taylor and Francis, London.
11. Gleadle P., Haslam C. An exploratory study of an early stage R&D-intensive firm under financialization. Accounting Forum 2010, 34(1):54-65.
12. House of Commons Trade and Industry Committee, House of Commons Trade and Industry Committee HC, (87) Session 2002-03 (UK: Biotechnology Industry). http://www.publications.parliament.uk/pa/cm200203/cmselect/cmtrdind/1282/1282.pdf.
13. Hopkins M.M., Martin P.A., Nightingale P., Kraft A., Mahdi S. The myth of the biotech revolution: an assessment of technological, clinical and organisational change. Research Policy 2007, 36(4):566-589. http://www.sheffield.ac.uk/content/1/c6/08/15/66/RP%20Myths%20III.pdf.
14. Lazonick W., O'Sullivan M. Maximizing shareholder value: a new ideology for corporate governance. Economy and Society 2000, 29(1):13-35.
15. Lazonick W. The quest for shareholder value: stock repurchases in the US economy. Louvain Economic Review 2008, 74(4):479-540. http://www.newschool.edu/cepa/events/workshops/Lazonick%20Quest%20for%20Shareholder%20Value%2020081016.pdf.
16. Lazonick W, Tulum O. US Biopharmaceutical finance and the sustainability of the biotech boom. Copenhagen CBS 2008, Denmark. http://www2.druid.dk/conferences/viewpaper.php%3Fid=3577%26cf=29.
17. McMillan G.S., Narin F., Deeds D.L. An analysis of the critical role of public science in innovation-capital market: the case of biotechnology. Research Policy 2000, 29(1):1-8. http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6V77-3YCV04R-1&_user=128556&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000010578&_version=1&_urlVersion=0&_userid=128556&md5=83dc7734359363dce4b1b72c5bae0971.
18. Mazzucato M., Dosi G. Knowledge accumulation and industry evolution: pharma-biotech 2006, Cambridge University Press.
19. Newberry S., Robb A. Financialisation: constructing shareholder value...for some. Critical Perspectives on Accounting 2008, 19(5):741-763.
20. Prahalad C.K., Hamel G. The core competence of the corporation. Harvard Business Review 1990, 68(3):79-91.
21. Porter M. The competitive advantage of nations 1990, Free Press, New York.
22. Pisano G. Science business: the promise, the reality, and the future of biotech 2006, Harvard Business School Press.
23. Pisano G. Can science be a business? Lessons from biotech. Harvard Business Review 2006, 84(10):114-125.
24. Robinson DT, Stuart T. Just how incomplete are incomplete contracts? Evidence from biotech strategic alliances; 2001. http://w4.stern.nyu.edu/emplibrary/Robinson01.pdf.
25. Standing S., Standing C., Lin C. A framework for managing knowledge in strategic alliances in the biotechnology sector. Systems Research and Behavioral Science 2008, 25(6):783-796.
26. The Times. Players that could cash in chips in the biotech game of roulette. London, England Saturday January 24th 2009. Author: Nick Hasell. http://business.timesonline.co.uk/tol/business/markets/article5576904.ece.